Detalles de la búsqueda
1.
Current treatment and recent progress in gastric cancer.
CA Cancer J Clin
; 71(3): 264-279, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33592120
2.
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.
Nature
; 603(7903): 942-948, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35322232
3.
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.
Nature
; 600(7890): 727-730, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34912120
4.
Locally advanced mismatch repair-deficient gastroesophageal junction cancer: Diagnosis, treatment modifications, and monitoring.
CA Cancer J Clin
; 74(2): 123-131, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-37849051
5.
Global Ring Study to Investigate the Comparability of Total Assay Performance of Commercial Claudin 18 Antibodies for Evaluation in Gastric Cancer.
Lab Invest
; 104(1): 100284, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37949357
6.
Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy.
Int J Cancer
; 154(12): 2142-2150, 2024 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38447003
7.
Whole-transcriptome sequencing in advanced gastric or gastroesophageal cancer: A deep dive into its clinical potential.
Cancer Sci
; 115(5): 1622-1633, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38429886
8.
Total neoadjuvant therapy in oesophageal and gastro-oesophageal junctional adenocarcinoma.
Br J Cancer
; 130(1): 9-18, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37898721
9.
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.
Br J Cancer
; 130(3): 476-482, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38135713
10.
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
Lancet
; 401(10389): 1655-1668, 2023 05 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37068504
11.
Apatinib Plus Toripalimab (Anti-PD1 Therapy) as Second-Line Therapy in Patients With Advanced Gastric or Esophagogastric Junction Cancer: Results From a Randomized, Open-Label Phase II Study.
Oncologist
; 29(4): 364-e578, 2024 Apr 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38366886
12.
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
N Engl J Med
; 384(13): 1191-1203, 2021 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33789008
13.
Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma.
Cancer Immunol Immunother
; 73(8): 144, 2024 Jun 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38832979
14.
Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer.
Cancer Immunol Immunother
; 73(7): 119, 2024 May 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38713205
15.
Long-Term Outcome of Proximal Gastrectomy for Upper-Third Advanced Gastric and Siewert Type II Esophagogastric Junction Cancer Compared With Total Gastrectomy: A Propensity Score-Matched Analysis.
Ann Surg Oncol
; 31(5): 3024-3030, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38372863
16.
Multimodal Therapy Versus Primary Surgery for Gastric and Gastroesophageal Junction Diffuse Type Carcinoma, with a Focus on Signet Ring Cell Carcinoma: A Nationwide Study.
Ann Surg Oncol
; 31(3): 1760-1772, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38127213
17.
Immunotherapy combined with apatinib in the treatment of advanced or metastatic gastric/gastroesophageal tumors: a systematic review and meta-analysis.
BMC Cancer
; 24(1): 603, 2024 May 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38760737
18.
Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials.
BMC Cancer
; 24(1): 240, 2024 Feb 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-38383390
19.
Cancer of the esophagus and esophagogastric junction-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
CA Cancer J Clin
; 67(4): 304-317, 2017 07 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28556024
20.
Implementation of perioperative FLOT compared to ECX/EOX chemotherapy regimens in resectable esophagogastric adenocarcinomas: an analysis of real-world data.
Acta Oncol
; 63: 322-329, 2024 May 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38745482